$GSK — WATCHLIST 📊 | 6 MONTHS THESIS

$GSK — WATCHLIST 📊 | 6 MONTHS THESIS 🎯 latest | Rev $1.9B | EPS $1.26 vs $1.16 🟢 💡 Consensus EPS was $1.16; actual $1.26 signals near-term operational strength. However, the market appears to price in limited re-rating potential, likely due to patent cliff concerns and a lack of near-term catalysts. The variant view is that this beat will not sustain above-average forward returns from current levels. 📉 Reward/risk: 1.3:1 🏢 Business Quality: 7/10 - Diversified pharma with strong commercial execution but facing mid-term patent expirations and pipeline uncertainty that cap multiple expansion. 📊 Valuation: fair — using a reference-class approach, the stock offers base upside of 5.6% to $54.98 with 4.4% downside to $49.78, producing a risk/reward of... 🔮 Catalyst: N/A — recent Q2 earnings already released 📊 Our read: WATCHLIST. Full analysis → https://stockduty.xyz/s/GSK0624

🎯 latest | Rev $1.9B | EPS $1.26 vs $1.16 🟢